Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Rohto Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4527   JP3982400008

ROHTO PHARMACEUTICAL CO., LTD.

(4527)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Face value: In China men's skincare boom, startups, global investors seek rich glow

12/11/2020 | 02:57am EDT
Liu Yuxuan, 22, a student, puts on his make-up at a restroom in a shopping mall in Shanghai

BEIJING/SHANGHAI (Reuters) - China's radiant male skincare market has a fresh shine: A raft of domestic startups is tapping global investors for funds, with ambitions to rival giants like L'Oreal in a billion-dollar business serving image-conscious millennial men like Hou Junru.

The 24-year-old Shanghai education worker got into skincare as a student and splurged more than $1,000 on creams and lotions in e-commerce firm Alibaba's giant Nov. 11 Singles Day promotion. "My need is to keep the skin moist and look pale," said Hou.

It's a priority shared by many of his peers, influenced by the spread of social media and South Korean pop culture that embraces a softer version of masculinity. Already the biggest in the world, the Chinese men's facial skincare market is forecast to hit 12.5 billion yuan ($1.90 billion) this year - and expand 50% to 18.5 billion yuan in 2025, research firm Mintel estimates.

Market research provider Euromonitor International estimates the men's skincare business in China, excluding post-shave products, was last year already more than three times the size of the U.S. market in dollar terms and more than twice the size of South Korea - with value growth through 2024 seen easily outstripping both.

Drawing on the huge reach of online retailers like Alibaba and JD.com, at least 10 new Chinese male skincare brands have been set up this year, according to media reports.

"A great number of small brands are emerging through online channels," Mintel said in a recent report. The "online shopping experience enables men to choose what they want quickly ... online retailers can make it easier for men to seek out information and tips than in offline stores."

Six of the new players between them raised more than 300 million yuan between them, the founder of one brand told Reuters. Bertelsmann Asia Investments said it has invested in a new Shanghai brand, without saying how much, while others like SIG Asia and Redpoint Ventures have also placed sector bets, according to domestic media reports and startup research database CB Insights.

To be sure, with a combined share of 60%, according to Mintel, the China market remains dominated by three big foreign players - France's L'Oreal, Nivea maker Beiersdorf of Germany, and Japan's Rohto, home of the OXY brand. L'Oreal declined to comment for this article, while Beiersdorf and Rohto didn't immediately respond to requests for comment.

Still, beyond that dominance lies a hefty, fragmented chunk to be targeted by new local startups, hoping to emulate the success of Perfect Diary, a red-hot Chinese women's cosmetics brand whose parent raised $617 million in a Nasdaq listing last month.

'DRAGON BLOOD'

Among the new breed of male skincare firms is Coen, founded in September by Huang Kai, a Xiamen-based entrepreneur who has shuttered his previous business selling men's apparel to focus on the beauty beat, with goods manufactured by firms in Guangzhou.

Huang, 31, said sales at Coen - a name that translates to "scientific and grateful" - topped 1 million yuan in two months via stores on e-commerce marketplaces. A 120 millilitre bottle of its flagship cleanser, 'Dragon Blood', retails for 64.90 yuan ($9.90) on Alibaba's Tmall platform.

With products like a beard depilatory cream in the pipeline Huang said he was in talks to raise funds from investors for what he described as a huge opportunity to tap new generations more open to skincare. "There are more than 200 million men born (in China) after 1995," said Huang.

A half-dozen of this year's bevy of startups have together already raised more than 300 million yuan, Huang said, declining to say which potential investors he's talking to.

Bertelmann Asia Investments Vice President Cindy Zhu told Reuters her firm has invested in Shanghai-based men's skincare company Just a Cool Brand (JACB), set up this year. Zhu said the fund believed the growth momentum in China's cosmetics market would continue.

"JACB will provide more professional products that may appropriately meet the skin care requirements of Chinese men consumers," said Zhu. JACB was not reachable for comment.

According to the CB Insights database, meantime, Redpoint Ventures and SIG Asia have invested in Make Essense, based in Shenzhen. Make Essense, SIG and Redpoint did not respond to Reuters' inquiries.

COLOUR COSMETICS?

One major hurdle for the new breed of Chinese suppliers will be persuading customers who have used well-known foreign brands for years to switch over to them.

Education worker Hou, for instance, said he doesn't use new domestic goods, opting for brands like France's Guerlain and La Mer instead. "These products are used on your face so I don't want to try brands I haven't heard of," he said.

But others remain open to the possibility. University student Liu Yuxuan, 22, typically uses Clinique and Estee Lauder but would consider domestic brands that offer value for money. "Chinese brands are more down-to-earth," said Liu.

One avenue of possibility for domestic brands could be to expand into colour cosmetics like eye shadow - still a niche but growing segment, according to JD.com and Alibaba numbers.

"Most men's products are boring," said Hou.

"Why won't brands give us men more innovative products? Like women I also need skincare to maintain moisture and look white. I will buy if they are good!"  

($1 = 6.5575 Chinese yuan renminbi)

(Reporting by Sophie Yu in Beijing and Brenda Goh in Shanghai; Editing by Kenneth Maxwell)

By Sophie Yu and Brenda Goh


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BEIERSDORF AG 0.58% 103.25 Delayed Quote.9.33%
L'ORÉAL S.A. -0.28% 390.3 Real-time Quote.25.58%
ROHTO PHARMACEUTICAL CO., LTD. -2.44% 2837 End-of-day quote.-7.14%
SIG PLC -6.15% 51.15 Delayed Quote.62.48%
All news about ROHTO PHARMACEUTICAL CO., LTD.
05/21ROHTO PHARMACEUTICAL  : Consolidated Financial Results for the Fiscal Year Ended..
PU
03/30ROHTO PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
02/17ROHTO PHARMACEUTICAL  : Attributable Profit Drops 12% in April-December 2020
MT
2020FACE VALUE : In China men's skincare boom, startups, global investors seek rich ..
RE
2020ROHTO PHARMACEUTICAL  : Fiscal H1 Profit Slips 15%
MT
2020ROHTO PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
2020ROHTO PHARMACEUTICAL  : Consolidated Financial Results for the First Quarter of ..
PU
2020ROHTO PHARMACEUTICAL  : to begin stem cell clinical test for COVID-19 in August
AQ
2020ROHTO PHARMACEUTICAL  : Drugmaker eyes stem cell clinical test for coronavirus t..
AQ
2020ROHTO PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
More news
Financials
Sales 2021 182 B 1 655 M 1 655 M
Net income 2021 14 148 M 128 M 128 M
Net Debt 2021 - - -
P/E ratio 2021 22,9x
Yield 2021 0,95%
Capitalization 324 B 2 935 M 2 936 M
Capi. / Sales 2021 1,77x
Capi. / Sales 2022 1,74x
Nbr of Employees 6 619
Free-Float 86,0%
Chart ROHTO PHARMACEUTICAL CO., LTD.
Duration : Period :
Rohto Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROHTO PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 3 310,00 JPY
Last Close Price 2 837,00 JPY
Spread / Highest target 33,9%
Spread / Average Target 16,7%
Spread / Lowest Target 3,98%
EPS Revisions
Managers and Directors
NameTitle
Masashi Sugimoto President & Representative Director
Masamitsu Inoue Manager-Accounting & Finance
Kunio Yamada Chairman
Shingo Torii Independent Outside Director
Haruka Mera Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ROHTO PHARMACEUTICAL CO., LTD.-7.14%2 935
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795